We're working on profiling this company soon. Let us know you're interested by sending us a request here »
We're working hard to bring you this company's profile. Register here to get an alert as soon we're done.
In the meantime, if you are interested in participating in placements on this stock click "Follow" on the toolbar above.
ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results...
Read ArticleOrthocell wins Singaporean approval for its Remplir nerve-repair product Lumos wraps up $10 million...
Read ArticleThere have been some big moves in the healthcare sector on Thursday. For example, the two ASX health...
Read ArticleHealthcare stocks are doing relatively well globally in 2024 The sector could see more recovery as...
Read ArticleASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing;...
Read ArticleNoxopharm says two novel drug candidates significantly reduced glioblastoma (brain cancer) cell gro...
Read ArticleThis article is part of the daily news updates from FNArena.com. Stay informed with the latest finan...
Read ArticleS&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expec...
Read ArticleThe EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-l...
Read ArticleThe ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biot...
Read ArticleLooking for exposure to the healthcare sector in FY 2025? If you are, then check out the three ASX s...
Read ArticleCyclopharm (ASX:CYC) has announced that Technegas received Pass-Through status from the US C...
Read ArticleThe ASX200 closed up 0.4% – thanks to a very small rise in Australia’s latest Gross Domestic Product...
Read ArticleS&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biot...
Read ArticleThe ASX200 closed the day up 0.8%. All sectors bar one finished in the green. Real-estate lead th...
Read ArticleASX drops over 1pc as tech, retail, banks fall; energy resists Bond yields surge, impacting goldies...
Read ArticleResearch shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase th...
Read ArticleASX Health sector was in correction territory in April Why is the health sector different from othe...
Read ArticleThere’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to c...
Read ArticleWhen your columnist caught up with Universal Biosensors chief John Sharman early last Tuesday, he wa...
Read ArticleDR BOREHAM’S CRUCIBLE: UNIVERSAL BIOSENSORS By TIM BOREHAM When your columnist caught up with Univer...
Read Article19 Mar 2024 - A snapshot of the stocks on the move, featuring Cyclopharm (ASX:CYC), lonic Rare Earth...
Read ArticleCyclopharm (ASX:CYC) announced that its first USA Technegas clinical patients were imaged last wee...
Read ArticleThe company said these events follow the US FDA approval of Technegas last October and the s...
Read ArticleASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essenti...
Read ArticleWelcome to the FNArena Corporate Results Monitor. Today's Reports: ((4DX)) - 4DMedical ((APM)) - A...
Read ArticleViking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on p...
Read ArticleRadiopharmaceutical company Cyclopharm (ASX:CYC) has announced the appointment of Jason Smit...
Read ArticleXi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for t...
Read ArticleNews relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD f...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a sma...
Read ArticleThe Fletcher Building Ltd (ASX: FBU) share price has returned from its suspension and crashed deep...
Read ArticleAsk any chief of a development-stage biotech about the prospect of a partnering or licencing deal an...
Read ArticleThe good news for income investors is that there are a lot of dividend stocks to choose from on the...
Read ArticleFDA approval for Cyclopharm’s device-as-a-drug is welcome news, Tim Boreham reports. By Tim Boreham...
Read ArticleASX health sector falls in line with broader markets as macroeconomic factors continue to create vo...
Read ArticleMany of Australia's top brokers have been busy adjusting their financial models again, leading to t...
Read ArticleToday is a good day to be a CSL Limited (ASX: CSL) shareholder. That's because later today the biot...
Read ArticleIf you want to boost your income portfolio this week, then it could be worth checking out the high-...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) has just...
Read ArticleWith so many shares to choose from on the ASX, it can be difficult to decide which ones to buy. The...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a sizeable decline...
Read ArticleThe US FDA has approved Cyclopharm's (ASX:CYC) Technegas for the diagnosis and management of...
Read ArticleThe ASX200 shed 0.2 of a per cent today as the market awaits the Reserve Bank’s interest rates decis...
Read ArticleStockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might h...
Read ArticleSydney-based Cyclopharm is preparing to send hundreds of its generators to the US for use in diagnos...
Read ArticleCyclopharm (ASX:CYC) receives US FDA approval to commence commercial sales of its novel drug candida...
Read ArticleAussie Futures lower, but shares likely to show reilience RBA cash rate decision to be the main foc...
Read ArticleL’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supr...
Read ArticleAccording to the World Health Organisation (WHO), cancer is the leading cause of death globally. WHO...
Read ArticleThe FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergenc...
Read ArticleThe US market closed slightly higher on Friday but overall finished the week lower as concerns res...
Read ArticleEarnings reports dominated headlines in August Despite solid results from ASX healthcare giants, th...
Read ArticleAustralian biotech has attracted US investments in the last five years Among ASX stocks to get fund...
Read ArticleWelcome to the FNArena Corporate Results Monitor. Today's Reports: ((ABY)) - Adore Beauty ((ASG))...
Read ArticleBiotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two g...
Read ArticleLocal markets have pedalled furiously since lunch to bring the benchmark to +0.35%. CBA posts recor...
Read ArticleThe US FDA has completed inspection of Cyclopharm’s facility Next Science says XPERIENCE reduces kn...
Read ArticleThe end of pandemic and higher rates have subdued biotech market But there are signs now the sector...
Read ArticleASX chopped about sideways, losing any slight semblance of fizz at close: -0.063% IT, Discretionar...
Read ArticleBrisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “gam...
Read ArticleSmall cap health stocks are not known to pay dividends But there’s a handful of such stocks on the...
Read ArticleBiotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We...
Read ArticleJoe Biden might have snubbed our leaders in favour of dealing with a wee $US31 trillion debt issue a...
Read ArticleMany Aussie biotechs have endured a long wait to secure US Food and Drug Administration (FDA) approv...
Read ArticleCyclopharm (ASX:CYC) has announced that it has been notified that the US FDA will inspect th...
Read ArticleThe ASX will open flattish on Tuesday Crude prices rise another 2pc overnight The market awaits the...
Read ArticleBy Mark Woodruff Guide: The FNArena database tabulates the views of eight major Australian and inter...
Read ArticleArtificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discove...
Read ArticleShareCafeOPEC oil cut gives Energy sector a big boost The Dow Jones Industr...
Read ArticleShareCafeDeutsche Bank the latest international bank to tumble Stocks rose...
Read ArticleSeveral ASX health stocks are seeking US FDA approval for drugs/devices in the near future Telix P...
Read ArticleThe FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have g...
Read ArticleJapanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based devic...
Read ArticleAll Ordinaries Index (ASX: XAO) shares closed up 0.7% on Friday. That helped the All Ords post a ga...
Read ArticleASX health stocks have been out of favour this year with rotation away from growth to value sector...
Read ArticleWe take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks fr...
Read ArticleASX 200 ends flat again Small caps gain a little bit ELO, DRO and EOS rise like legends There ar...
Read ArticleASX 200 ends flat as Small caps s wee bit lower OLL investment sparks share price surge We’re p...
Read ArticleBlood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks...
Read ArticleShareCafeKey week for US economic data as indexes produce strong weekly gains ...
Read ArticleShareCafeBiden Administration moves to ban chip sales into China The Dow Jo...
Read ArticleRadiopharmaceutical company Cyclopharm Limited (ASX:CYC) has announced results for the six-m...
Read ArticleThe ASX 200 is set to open higher on Wednesday Wall Street was mixed overnight Oil is at the lowest...
Read ArticleUS FDA approves the first clinical trial using naturally derived psychedelic drugs It could open po...
Read ArticleBotanix’s FDA submission gets accelerated Release extends contract with Medgate to use the ResAppDx...
Read ArticleA recent research reveals which biotech segments VCs are ploughing billions of dollars into We list...
Read ArticleAn additional news report on the recommendation, valuation, forecast and opinion changes for ASX-lis...
Read ArticleThe Healthcare sector has been struggling as the pandemic wanes But most money managers are still b...
Read ArticleThe healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak mark...
Read ArticleHighlights The ASX 200 index is likely to open lower on Tuesday tracking lower global equities....
Read ArticleHighlights Companies like Beacon Minerals, Cyclopharm and Sigma Healthcare will be turning ex-di...
Read ArticleBiotech sector has had a tough time recently But there are signs of things improving this year A lo...
Read ArticleTelehealth was already a growing space even before the pandemic, but COVID had launched it into the...
Read ArticleThe ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial t...
Read ArticleThe ASX 200 Health Index (XHJ) is falling by 0.3% at the time of writing, compared to the broader in...
Read ArticleThe ASX is suffering today in what could be a reaction to a disastrous session in the United States...
Read ArticleAt the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, be...
Read ArticleIt’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and...
Read ArticleThe life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, th...
Read ArticleIt’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 los...
Read ArticleHe’s baaack! Fresh from founding and listing immune-oncology play Chimeric, Paul Hopper can add Radi...
Read ArticleIt’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 los...
Read ArticleHighlights The rising population and the rise in health issues are increasing the demand for hea...
Read ArticleAlthough earnings results were the main theme in August, there were also some notable healthcare bre...
Read ArticleIDT Australia (ASX:IDT) jumped more than 20% after announcing that it has formalised activities with...
Read ArticleWall Street rose ahead of world centrals banks meeting this week All three US stock market indexes b...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 7...
Read ArticleThe ASX200 health stocks index (XHJ) fell by 0.14% this morning, compared to the broader index which...
Read ArticleThe ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the...
Read ArticleAn additional news report on the recommendation, valuation, forecast and opinion changes for ASX-lis...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 7...
Read ArticleEach week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Relative Strength In...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52...
Read ArticleEach week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Relative Strength In...
Read ArticleCyclopharm Limited (ASX: CYC) shares are on the rise today after the company released a trading upd...
Read ArticleWall Street higher as US jobless claims plunged All the three major US benchmarks rose overnight, af...
Read ArticleOver the past month, a number of US FDA approvals have moved the share prices of global pharma stock...
Read ArticleClosing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at th...
Read ArticleCyclopharm (ASX:CYC) shares are down by more than 40 per cent in early trading after the US Food and...
Read ArticleCyclopharm Limited (ASX: CYC) shares are taking an absolute pummelling today. At the time of writin...
Read ArticleStockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) per...
Read ArticleHere’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has ret...
Read ArticleThe diagnostics imaging industry has come a long way since the days of X-rays and CT scans – two tec...
Read ArticleIt was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies relea...
Read ArticleFor all the leaps and bounds in medical science, the know-how behind detecting diseases hasn’t chang...
Read ArticleThe Cyclopharm Limited (ASX: CYC) share price is dipping today after the company released its 2021...
Read ArticleThe capital raisings boom on the ASX is continuing in 2021 with nearly $10 billion raised in the fir...
Read ArticleInflammatory diseases company Pharmaxis (ASX:PSX) this month welcomed a familiar biotech name to the...
Read ArticleWhat’s the difference between a wind tunnel and a set of lungs? For mechanical engineer Andreas Four...
Read ArticleHere’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks f...
Read Article2021 is set to be another big year for ASX capital raisings with solid volumes so far in 2021. In th...
Read ArticleSummary Radiopharmaceutical company Cyclopharm completed A$30 million placement with overwhelmin...
Read ArticleASX-listed diagnostic imaging business Cyclopharm is seeking a capital injection to fund its rollout...
Read ArticleThe Cyclopharm Limited (ASX: CYC) share price was sent soaring today after the company announced a...
Read ArticleThe Cyclopharm Limited (ASX: CYC) share price continues to bask in the glory of its clinical trial...
Read Article09 Sep 2020 - Cyclopharm (ASX:CYC) today announced a new research collaboration with McMasters Unive...
Read ArticleFresh off its first sale in the US and positive results from a John Hopkins School of Medicine study...
Read ArticleCan you tell whether a person has COVID-19 by their cough? Research says it’s highly unlikely you, o...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleThe Cyclopharm Limited (ASX: CYC) share price has rocketed out of the gates this morning after the...
Read Article14 Apr 2020 - Cyclopharm (ASX:CYC) is pleased to announce that the United States Food and Drug Admin...
Read ArticleAustralian company Cyclopharm (ASX:CYC) has announced that the US FDA has granted it a full...
Read ArticleYesterday, Stockhead reviewed the small caps that are devising treatments to fight cancer. There are...
Read ArticleInternational research suggests shares in companies that buy in their own equities are more likely t...
Read ArticleInternational research suggests shares in companies that buy in their own equities are more likely t...
Read ArticleCyclopharm Limited (ASX: CYC) provides an update on progressing its strategy during FY19, which inc...
Read ArticleAir pollution is a growing problem that in recent days has reached our own backyard. Because of the...
Read ArticleInternational research suggests shares in companies that buy in their own equities are more likely t...
Read ArticleIn the Australian health care system, three levels of government are responsible for providing unive...
Read ArticleFor a certain generation of investors the word ‘laser’ is indelibly tied to a Dr Evil reference. Ove...
Read ArticleInternational research suggests shares in companies that buy in their own equities are more likely t...
Read ArticleInternational research suggests shares in companies that buy in their own equities are more likely t...
Read ArticleInternational research suggests shares in companies that buy in their own equities are more likely t...
Read ArticleInternational research suggests shares in companies that buy in their own equities are more likely t...
Read ArticleInternational research suggests shares in companies that buy in their own equities are more likely t...
Read ArticleInternational research suggests shares in companies that buy in their own equities are more likely t...
Read ArticleThe TechKnow Invest Roadshow provides retail and institutional investors, as well as brokers, an opp...
Read ArticleInternational research suggests shares in companies that buy in their own equities are more likely t...
Read ArticleInternational research suggests shares in companies that buy in their own equities are more likely t...
Read ArticleInternational research suggests shares in companies that buy in their own equities are more likely t...
Read ArticleRadiopharmaceutical company Cyclopharm (ASX: CYC) has announced four management appointments...
Read ArticleInternational research suggests shares in companies that buy in their own equities are more likely t...
Read ArticleInternational research suggests shares in companies that buy in their own equities are more likely t...
Read ArticleInternational research suggests shares in companies that buy in their own equities are more likely t...
Read ArticleInternational research suggests shares in companies that buy in their own equities are more likely t...
Read ArticleInternational research suggests shares in companies that buy in their own equities are more likely t...
Read ArticleInternational research suggests shares in companies that buy in their own equities are more likely t...
Read ArticleInternational research suggests shares in companies that buy in their own equities are more likely t...
Read ArticleInternational research suggests shares in companies that buy in their own equities are more likely t...
Read ArticleInternational research suggests shares in companies that buy in their own equities are more likely t...
Read ArticleInternational research suggests shares in companies that buy in their own equities are more likely t...
Read ArticleInternational research suggests shares in companies that buy in their own equities are more likely t...
Read ArticleInternational research suggests shares in companies that buy in their own equities are more likely t...
Read ArticleInternational research suggests shares in companies that buy in their own equities are more likely t...
Read ArticleInternational research suggests shares in companies that buy in their own equities are more likely t...
Read ArticleInternational research suggests shares in companies that buy in their own equities are more likely t...
Read Article
Open an account with an online broker of your choice. If you do not have an existing broker, consider Vested Equities' A$9.50 flat fee platform.
Sign up now »Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.
